LBRX
LB Pharmaceuticals Upsizes IPO to $285M, Marks First Major Biotech Listing in Months
LB Pharmaceuticals; IPO; biotech; $285 million; LBRX; schizophrenia; Phase III; public offering; Nasdaq; 2025 biotech IPOs
Actionable Insights Powered by AI
LB Pharmaceuticals; IPO; biotech; $285 million; LBRX; schizophrenia; Phase III; public offering; Nasdaq; 2025 biotech IPOs